IP Library Granted Patent US 11,673,951
Granted Patent B2
US 11,673,951 · App. 16/684,237 · Granted Jun 13, 2023

Anti-PD1 antibodies and their use as therapeutics and diagnostics

Inventors: Kang Li (Beijing, CN); Tong Zhang (Beijing, CN); Jing Song (Beijing, CN); Lanlan Xu (Beijing, CN); Qi Liu (Beijing, CN); Hao Peng (Beijing, CN)
Assignee: BEIGENE SWITZERLAND GMBH
C07K16/2803A61K39/39591C07K16/2818A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/52C07K2317/53C07K2317/55C07K2317/565C07K2317/567C07K2317/569C07K2317/70C07K2317/71C07K2317/73C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,673,951
App. No.
16/684,237
Granted
Jun 13, 2023
Kind
B2
Abstract

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Claims (12)

1. A polynucleotide encoding a heavy chain variable region of an antibody or antigen-binding fragment thereof that specifically binds to PD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementary determining region (CDR) 1 according to SEQ ID NO: 31, a heavy chain CDR2 according to SEQ ID NO: 32, and a heavy chain CDR3 according to SEQ ID NO: 33.

2. The polynucleotide of claim 1 , further encoding a light chain variable region of the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 according to SEQ ID NO: 34, a light chain CDR2 according to SEQ ID NO: 35, and a light chain CDR3 according to SEQ ID NO: 36.

3. The polynucleotide of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region according to SEQ ID NO: 24 and a light chain variable region according to SEQ ID NO: 26.

4. The polynucleotide of claim 1 , wherein the polynucleotide comprises a sequence according to SEQ ID NO: 23.

5. The polynucleotide of claim 2 , wherein the polynucleotide comprises a sequence according to SEQ ID NO: 25.

6. The polynucleotide of claim 5 , wherein the polynucleotide comprises SEQ ID NO: 23 and SEQ ID NO: 25.

7. The polynucleotide of claim 1 , wherein the antibody is a monoclonal antibody.

8. The polynucleotide of claim 7 , wherein the monoclonal antibody has an IgG4 heavy chain.

9. A polynucleotide encoding a humanized monoclonal antibody that binds to PD-1, wherein the antibody comprises a heavy chain amino acid sequence comprising a heavy chain variable region of SEQ ID NO: 24 and a heavy chain IgG4 Fc region of SEQ ID NO: 88, and a light chain amino acid sequence comprising the amino acid sequence of a light chain Ig kappa C-region deposited as NCBI Accession No. P01834 and a light chain variable region of SEQ ID NO: 26.

10. A humanized monoclonal antibody that binds PD-1 comprising: a heavy chain variable region of SEQ ID NO: 24, a heavy chain IgG4 Fc region of SEQ ID NO:

88, a light chain Ig kappa C-region deposited as NCBI Accession No. P01834, and a light chain variable region of SEQ ID NO: 26.

11. The humanized monoclonal antibody that binds PD-1 of claim 10 , wherein the antibody consists of: the heavy chain variable region of SEQ ID NO: 24, the heavy chain IgG4 Fc region of SEQ ID NO: 88, the light chain Ig kappa C-region deposited as NCBI Accession No. P01834, and the light chain variable region of SEQ ID NO: 26.

Assignments (4)
CHANGE OF NAME Recorded Sep 23, 2025
From: BEIGENE SWITZERLAND GMBH
To: BEONE MEDICINES I GMBH
Reel/Frame 072872/0076 →
CHANGE OF ASSIGNEE ADDRESS Recorded Nov 4, 2021
From: BEIGENE SWITZERLAND GMBH
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 058267/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: LI, KANG; ZHANG, TONG; SONG, JING; XU, LANLAN; LIU, QI; PENG, HAO
To: BEIGENE, LTD.
Reel/Frame 054423/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 054423/0366 →
Continuity (7)
Continuation 15978695 · May 14, 2018
Continuation 15802093 · Nov 2, 2017
Continuation 14736966 · Jun 11, 2015
Division 14194797 · Mar 2, 2014
Division 14076214 · Nov 10, 2013
Continuation PCTCN2013083467 · Sep 13, 2013
Related Publication 20200216535A1 · Jul 9, 2020